Aleyasin, Seyed Ahmad
Moradi, Arash
Abolhasani, Naeimeh
Abdollahi, Mahvash
Funding for this research was provided by:
National Institute of Genetic Engineering and Biotechnology (667)
Article History
Received: 19 September 2023
Accepted: 30 November 2023
First Online: 1 February 2024
Declarations
:
: All authors read the manuscript, and no competing interests were declared.
: The study underwent a rigorous ethical review process by the Ethical Committee of the National Institute of Genetic Engineering and Biotechnology (NIGEB) before its approval (Ethical code #: IR.NIGEB.EC1398.12.3.A). The research team followed all relevant guidelines and regulations to ensure all participants’ safety and well-being. Participants were fully informed of the research’s purpose and procedures and provided an informed consent form before participating. The consent form detailed the use of their clinical samples and personal data throughout the study, which was to be conducted under their physician’s supervision. The research team prepared the informed consent form with the utmost care, and all participants willingly signed it before participating. Participants were free to withdraw their consent at any point during the study. Throughout the study, the research team upheld the highest ethical standards and strictly adhered to all relevant regulations to ensure the privacy and confidentiality of all participants’ data.
: Not applicable.